Condition

Recurrent Head and Neck Squamous Cell Carcinoma clinical trials and research

• 22Clinical trials
• 1New in 30 days
• 33Countries

Newest Recurrent Head and Neck Squamous Cell Carcinoma clinical trials

All recruiting trials (22)

• TMV vaccine alone or with toripalimab for recurrent head and neck cancer

  This study tests a personalized TMV vaccine, alone and with toripalimab, in adults whose head and neck cancer has returned and is planning salvage surgery.

  Recruiting Phase 1 Metaclipse Therapeutics Corporation · Houston, Texas · NCT07898124

• Ficerafusp alfa (BCA101) with pembrolizumab in first-line PD-L1-positive recurrent/metastatic HNSCC: alternative dosing vs weekly dosing

  This study tests whether a different dosing approach of ficerafusp alfa plus pembrolizumab works as well as the standard weekly dosing in adults with newly diagnosed or recurrent/metastatic PD-L1-positive head and neck cancer.

  Recruiting at 7 sites Phase 2 Bicara Therapeutics · Fort Myers, Florida and 6 other locations · NCT07807163

• Morning versus afternoon immunotherapy for advanced or metastatic solid tumors

  This trial tests whether giving standard immune checkpoint inhibitor therapy in the morning versus the afternoon changes outcomes for adults with advanced or metastatic solid tumors.

  Recruiting Phase 4 OHSU Knight Cancer Institute · Portland, Oregon · NCT07405086

• Pembrolizumab plus short-course proton or X‑ray radiation before salvage surgery for recurrent head and neck cancer

  This study will try short-course proton or X‑ray radiation followed by pembrolizumab before salvage surgery in adults with recurrent head and neck squamous cell carcinoma who previously received radiation.

  Recruiting Phase 1/2 University of Cincinnati · Cincinnati, Ohio · NCT07213934

• Camonsertib added to precise radiation therapy for recurrent head and neck cancer

  This early-phase study tests whether the cancer drug camonsertib, given with targeted SBRT radiation, is safe and tolerable for people with recurrent or unresectable head and neck squamous cell carcinoma.

  Recruiting at 4 sites Phase 1 National Cancer Institute (NCI) · Duarte, California and 3 other locations · NCT07156227

• Re‑radiation with chemotherapy plus pembrolizumab versus pembrolizumab (± chemotherapy) for recurrent PD‑L1 positive head and neck cancer

  This trial tests whether adding re‑radiation with chemotherapy followed by pembrolizumab helps people with PD‑L1 positive (CPS≥1) locoregionally recurrent head and neck cancer live longer than pembrolizumab alone (with or without chemotherapy).

  Recruiting at 20 sites Phase 3 Universität des Saarlandes · Berlin and 23 other locations · NCT07026474

• Cemiplimab with or without CDX-1140 given before surgery for stage III-IV head and neck cancer

  This trial tests whether adding the immune stimulant CDX-1140 to cemiplimab before surgery helps shrink tumors in people with resectable stage III-IV head and neck squamous cell carcinoma.

  Recruiting at 12 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 11 other locations · NCT06980038

• Autologous tumor membrane vesicle (TMV) vaccine alone or with pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma

  This trial tests whether a vaccine made from a patient's own tumor (TMV), given alone or with pembrolizumab, can help people with recurrent or metastatic head and neck squamous cell carcinoma who had tumor tissue banked at surgery.

  Recruiting at 2 sites Phase 1 Emory University · Atlanta, Georgia and 1 other locations · NCT06868433

• Evaluating ficerafusp alfa with pembrolizumab for advanced head and neck cancer

  This study is testing a new treatment combining ficerafusp alfa and pembrolizumab to see if it helps people with advanced head and neck cancer feel better.

  Recruiting at 231 sites Phase 2/3 Bicara Therapeutics · Birmingham, Alabama and 230 other locations · NCT06788990

• Combining ASP-1929 photoimmunotherapy with pembrolizumab for treating recurrent head and neck cancer

  This study is testing if a new light-based treatment combined with pembrolizumab can help people with recurring head and neck cancer live longer compared to standard treatments.

  Recruiting at 21 sites Phase 3 Rakuten Medical, Inc. · Duarte, California and 21 other locations · NCT06699212

• Microfluidic blood test using tumor cell clusters and NK cell signals to predict outcomes in recurrent or metastatic head and neck squamous cell cancer

  This project will test whether a blood-based microfluidic test that looks at circulating tumor cell clusters and NK cell IFN-γ signals can help predict outcomes for people with recurrent or metastatic head and neck squamous cell carcinoma.

  Recruiting National Taiwan University Hospital · Zhubei, HsinChu County · NCT06678724

• Remote hearing tests for patients with head and neck cancer receiving chemotherapy or radiation

  This study is testing if remote hearing tests can help patients with advanced head and neck cancer keep track of their hearing loss during chemotherapy or radiation, making it easier for those who live far away to participate.

  Recruiting Emory University · Atlanta, Georgia · NCT06662058

• Combining lovastatin and pembrolizumab for advanced head and neck cancer treatment

  This study is testing if combining a cholesterol-lowering drug called lovastatin with an immunotherapy drug called pembrolizumab can help people with advanced head and neck cancer feel better and live longer.

  Recruiting at 2 sites Phase 2 Emory University · Atlanta, Georgia and 1 other locations · NCT06636734

• Combining cetuximab with pembrolizumab for advanced head and neck cancer

  This study is testing if adding cetuximab to pembrolizumab can help people with advanced head and neck cancer live longer and feel better compared to just using pembrolizumab alone.

  Recruiting at 192 sites Phase 3 National Cancer Institute (NCI) · Little Rock, Arkansas and 201 other locations · NCT06589804

• Comparing home and clinic administration of nivolumab for cancer treatment

  This study tests whether giving cancer patients their treatment at home instead of in a clinic makes them feel better and prefer their care more.

  Recruiting Phase 2 Mayo Clinic · Jacksonville, Florida · NCT06265285

• Combination treatment for advanced head and neck cancer

  This study is testing a new combination treatment for people with advanced head and neck cancer to see if it can boost their immune response and help fight the disease.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06239220

• Combining ficlatuzumab with cetuximab for advanced HPV-negative head and neck cancer

  This study is testing if adding a new drug called ficlatuzumab to cetuximab can help people with advanced HPV-negative head and neck cancer live longer and feel better compared to just using cetuximab with a placebo.

  Recruiting at 96 sites Phase 3 AVEO Pharmaceuticals, Inc. · Gilbert, Arizona and 111 other locations · NCT06064877

• Using dual imaging techniques to detect head and neck cancer

  This study is testing two new imaging techniques to see if they can better detect head and neck cancer in patients before surgery.

  Recruiting Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT05945875

• Using a radioactive drug to find cancer spread in head and neck patients

  This study is testing a new radioactive drug to see if it can help doctors find cancer spread in the lymph nodes of patients with head and neck cancer before surgery.

  Recruiting Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT05901545

• Combination of immunotherapy and chemotherapy for head and neck cancer treatment

  This study is testing if combining an immunotherapy drug with chemotherapy before and after surgery can help people with head and neck cancer do better.

  Recruiting Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT05726370

• Comparing an immunotherapy drug to chemotherapy and radiation for recurrent head and neck cancer after surgery

  This study is testing whether an immunotherapy drug called pembrolizumab can help people with recurrent head and neck cancer live longer compared to the usual treatment of chemotherapy and radiation.

  Recruiting at 119 sites Phase 2 National Cancer Institute (NCI) · Birmingham, Alabama and 177 other locations · NCT04671667

• Cetuximab treatment for advanced head and neck cancer after immunotherapy

  This study is testing if the drug Cetuximab can help people with advanced head and neck cancer who didn’t respond to or couldn’t tolerate previous immunotherapy treatments.

  Recruiting Phase 2 Wake Forest University Health Sciences · Winston-Salem, North Carolina · NCT04375384

Related topics

Quick answers

How many Recurrent Head and Neck Squamous Cell Carcinoma clinical trials are recruiting right now?

22, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 33 countries. The most sites are in United States (20 trials), Taiwan (4 trials), Germany (3 trials), Japan (2 trials), Australia (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 8, Phase 1: 5, Phase 3: 4, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →